Nuvation Bio Inc.

As of September 30, 2026, Nuvation Bio Inc. carries a market capitalization of 1.98B, placing it among publicly traded companies globally. Its enterprise value stands at 1.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Nuvation Bio Inc.'s next confirmed earnings release is scheduled for March 11, 2027.

As of September 30, 2026, Nuvation Bio Inc. has 352.92M shares outstanding.

These figures are as of September 30, 2026. The price-to-sales ratio is 9.66, and the price-to-book ratio stands at 8.67.

These figures are as of September 30, 2026. The EV/Sales ratio of 8.00 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.61B versus a market cap of 1.98B, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2026, Nuvation Bio Inc. maintains a current ratio of 7.45, meaning it holds 7.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 131.63, indicating elevated leverage, while an interest coverage ratio of -4.62 demonstrates limited ability to service its debt obligations.

Over the twelve months ended September 30, 2026, Nuvation Bio Inc. posted a negative return on equity (ROE) of -49.09, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -19.70, reflecting losses generated across the asset base. The company generates approximately 676,949.66 in revenue per employee across its workforce of 298.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.72 indicates how many times Nuvation Bio Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on November 6, 2026, Nuvation Bio Inc.'s stock has declined approximately 17.13% over the past 52 weeks. The 50-day moving average sits at 5.39, while the 200-day moving average is 5.36.

Over the twelve months ended September 30, 2026, Nuvation Bio Inc. generated 201.73M in revenue and converted that into -135.93M in net income, yielding earnings per share of -0.38. EBITDA reached -121.21M, while operating income came in at -123.40M.

As of September 30, 2026, Nuvation Bio Inc. holds 663.37M in cash and equivalents against 300.09M in total debt, resulting in a net debt position of 131.66M. Total book value stands at 227.98M, with working capital of 636.10M providing operational flexibility.

Nuvation Bio Inc. produced -106.19M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -1.98M in capital expenditures, free cash flow totaled -108.17M - equivalent to -0.31 per share.

Over the twelve months ended September 30, 2026, Nuvation Bio Inc. posted a gross margin of 85.79, reflecting its pricing power and cost economics. The operating margin of -61.17 and net profit margin of -67.38 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -5.43: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -11.22, meaning Nuvation Bio Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of September 30, 2026, Nuvation Bio Inc. has an Altman Z-Score of 0.65, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.